Caden Lane Black Friday Sale
Fine print flips promotion on its head.
In May 2019, a class-action lawsuit was filed against Boehringer Ingelheim Pharmaceuticals for allegedly deceptively marketing that the Combivent Respimat asthma inhaler will provide 120 doses when, according to plaintiffs, the inhaler contains far fewer dosages, sometimes less than half the advertised amount. (Ignacuinos et al v. Boehringer Ingelheim Pharmaceuticals, Inc., Case No. 19-cv-672, D. Conn.)
Fine print flips promotion on its head.
No woman should have to give birth without clean water.
Why regulators need to step in and what’s at stake.
Purported closing-down sale is deceiving consumers, with the help of AI.
Company hits snooze on promised marketing changes.